- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00696943
18F ML-10 for Early Detection of Response of Brain Metastases to SRS
An Open-label, Multi-center Study to Evaluate [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Stereotactic Radio Surgery (SRS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Early assessment of the efficacy of anti-cancer therapy is highly desirable and an unmet need in clinical oncology. Currently, treatment efficacy is mostly measured by following tumor size by anatomical imaging (CT scan or MRI). However, changes in tumor size may be observed only after several weeks to several months after completion of treatment. Meanwhile, in cases where there is no response, the patient is unnecessarily exposed to treatment's side effects, and precious time may be lost before the initiation of an alternative, potentially more beneficial line of therapy. Therefore, there is an urgent and serious need for better tools for monitoring of tumor response to anti-cancer treatments.
To address this need, [18F]-ML-10, a novel small molecular-weight probe (MW 205) was developed for clinical detection of apoptosis in vivo by positron emission tomography (PET). [18F]-ML-10 is a member of the ApoSense family of compounds, a novel class of molecular probes for molecular imaging of cell death. The first clinical indication for which [18F]-ML-10 is being developed is imaging of apoptosis in clinical oncology to monitor tumor response to radiation therapy.
Previous preclinical and clinical studies have substantiated the safety of [18F]-ML-10, its very high stability in vivo, its favorable biodistribution profile, and its efficacy in clinical detection of cell death. In preclinical studies, the selective retention of [18F]-ML-10 in the focus of the neurovascular cell death in cerebral ischemia was demonstrated in respective animal models. [18F]-ML-10 has been examined in two clinical trials in Uppsala Imanet, Sweden, and has been found safe in administration to healthy subjects and to elderly subjects with acute ischemic cerebral stroke. In these clinical trials, [18F]-ML-10 was also found efficacious in the clinical imaging of apoptosis, being either physiological apoptosis as observed in the testes in young healthy males, and pathological cell death, as observed in the brains of patients with acute ischemic cerebral stroke.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The Patient may only be included in the study if ALL of the following statements are fulfilled:
- Male or female patient diagnosed with metastatic non hematological cancer, with up to 4 brain metastases of which at least one has a minimal diameter of 1.5cm , as assessed by MRI (utilized for SRS planning) and is scheduled for SRS. These metastases will be defined as target lesions.
- Patient is ≥ 18 years of age at the time of signature of the informed consent form.
- Fully conscious patient who has been given written and verbal information, and has then provided an informed consent.
- Patient who is able to cooperate with the studies requirements to lie still during PET/CT imaging scans, which may last for up to 3 hours.
- ECOG performance status of 0, 1 or 2 at the time of enrollment.
- Patient with life expectancy ≥ 12 weeks.
Adequate renal function and adequate hepatic function as assessed by standard laboratory criteria and defined as:
- Creatinine clearance ≥ 60 ml/min/1.73m2according to Cockroft & Gault Formula
- Total bilirubin ≤ 1.5 times the ULN
- Aspargine aminotransferase (AST), alanine aminotransferase (ALT) ≤ 3 times the ULN in patients without liver metastases; ≤ 5 times the ULN in patients with liver metastases
- Serum calcium levels, adjusted to albumin level, within normal limits.
- For a female patient, pregnancy or breast-feeding are restricted. Woman of child bearing potential must have a negative serum pregnancy test at screening.
Exclusion Criteria:
If any apply, the patient must not be included in the study:
- Unstable medical condition, such as severe ischemic heart disease, liver disease or pulmonary disease, which may risk the patient during the study, as judged by the investigator.
- Any indication of imminent brain herniation
- Any known psychiatric disorder other than mild depression or anxiety.
- Known allergy to Gadolinium
- Other condition that might jeopardize the safety of the patient or the evaluation of the study results, as judged by the investigator.
- Treatment with any non-marketed investigational drug within 30 days prior to administration of [18F]-ML-10
- Patient who received Whole Brain Radiation Therapy (WBRT) within 6 months prior screening and/or planned to receive WBRT 8 weeks post SRS
- Patient receiving concurrent treatment with temozolamide or planned to receive temozolamide within 8 weeks post SRS
- Woman of child-bearing potential who is not using an adequate and medically acceptable contraceptive method. Men who do not agree to use effective contraception during the study and for a period of 60 days following the last administration of [18F]-ML-10.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-ML-10,
Pre-treatment baseline and post treatment follow-up 18F ML-10 PET/CT sessions.
|
[18F]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume).
The radiation dose of [18F]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of the change in the uptake of [18F]-ML-10 by the target lesion(s) in response to SRS, as observed by comparing the PET/CT scans before and after SRS. Target lesion is defined as having a minimal diameter of 1.5 cm
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of the relationship between the change in uptake of [18F]-ML-10 by the metastatic target lesions as observed in the PET/CT scans obtained before and after irradiation, and shrinkage of the metastatic target lesion, as assessed by MRI.
Time Frame: 3 months
|
3 months
|
Evaluation of the safety of [18F]-ML-10 when administered for 3 consecutive PET/CT scans to patients with brain metastases undergoing SRS.
Time Frame: one month
|
one month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yael Cohen, Aposense Ltd.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NST-CA005CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastasis to Brain of Unknown Primary
-
Hoffmann-La RocheFoundation Medicine, Inc.Active, not recruitingCancer of Unknown Primary SiteUnited Kingdom, Korea, Republic of, France, Australia, Germany, Austria, Croatia, Denmark, Finland, Greece, Hungary, Italy, Portugal, Spain, Japan, Brazil, Colombia, Mexico, Romania, Czechia, Norway, Thailand, Switzerland, Turkey, Nethe... and more
-
Imperial College LondonMerck Sharp & Dohme LLCActive, not recruitingCancer of Unknown Primary SiteUnited Kingdom
-
Peter MacCallum Cancer Centre, AustraliaRecruitingCancer of Unknown Primary SiteAustralia
-
Fudan UniversityRecruitingCancer of Unknown Primary SiteChina
-
M.D. Anderson Cancer CenterInnovent Biologics (Suzhou) Co. Ltd.Active, not recruiting
-
The Christie NHS Foundation TrustHoffmann-La Roche; ConcR; Durham UniversityActive, not recruitingCancer of Unknown Primary SiteUnited Kingdom
-
Fudan UniversityCompletedCancer of Unknown Primary SiteChina
-
University Hospital HeidelbergUnknown
-
M.D. Anderson Cancer CenterSanofi-SynthelaboCompletedUnknown Primary NeoplasmsUnited States
-
Rigshospitalet, DenmarkCompletedUnknown Primary TumorDenmark
Clinical Trials on ([18F]-ML-10)
-
Aposense Ltd.CompletedSolid Tumors | Brain Metastases
-
Aposense Ltd.UnknownHead and Neck Neoplasms | Carcinoma, Non-Small-Cell LungUnited States
-
Aposense Ltd.UnknownSolid Tumors | Brain MetastasesUnited States
-
Ampio Pharmaceuticals. Inc.Completed
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityCompletedCytokine Release Syndrome | Covid-19 PneumoniaPakistan
-
Novo Nordisk A/SCompleted
-
Dr Cipto Mangunkusumo General HospitalActive, not recruitingMechanical Ventilation ComplicationIndonesia
-
Institut Claudius RegaudActive, not recruitingTriple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mmFrance
-
Indonesia UniversityCompletedLaparoscopic NephrectomyIndonesia